- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biodexa Pharmaceuticals PLC DRC (BDRX)
The Biodexa Pharmaceuticals DRC share price today is 4.420, view NASDAQ BDRX stock exchange data. Track the latest Biodexa Pharmaceuticals DRC share price with real-time updates on BDRX stock performance including market cap, day range, 52-week range and dividend yield. Access BDRX charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.200
4.750
52 wk Range
2.860
96.500
BDRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.2004.750
52 wk Range
2.86096.500
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
BDRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Earnings
Latest Release
27-03-2026
EPS / Forecast
-3.05 / --
Revenue / Forecast
-- / --
Compare BDRX to Peers and Sector
Metrics to compare | BDRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipBDRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.3x | −22.5x | −0.5x | |
PEG Ratio | - | 0.05 | 0.00 | |
Price/Book | 0.2x | 4.6x | 2.6x | |
Price / LTM Sales | - | 74.9x | 3.2x | |
Upside (Analyst Target) | - | 82.4% | 48.3% | |
Fair Value Upside | Unlock | −24.9% | 5.6% | Unlock |
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTX240, for the treatment of gastrointestinal stromal tumors. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release therapeutics; MidaSolve, nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours; and MidaCore, a gold nanoparticle used for targeting sites of disease. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
FAQ
What Is the Biodexa Pharmaceuticals DRC (BDRX) Share Price Today?
The Biodexa Pharmaceuticals DRC share price today is 4.420.
What is the current Biodexa Pharmaceuticals DRC (BDRX) share price and day range?
As of 07-05-2026, the Biodexa Pharmaceuticals DRC share price is 4.420, with a previous close of 4.420. The share price has ranged from 4.200 to 4.750 today, while the 52-week range spans from 2.860 to 96.500.
What Is the Biodexa Pharmaceuticals DRC Market Cap?
As of today, Biodexa Pharmaceuticals DRC market cap is 2.870M.
What Is the Biodexa Pharmaceuticals DRC (BDRX) Share Price Target?
The average 12-month share price target for Biodexa Pharmaceuticals DRC is 36.055, with a high estimate of 36.05488385 and a low estimate of 36.05488385. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +715.72% Upside potential.
What Is Biodexa Pharmaceuticals DRC's Earnings Per Share (TTM)?
The Biodexa Pharmaceuticals DRC EPS (TTM) is -58.183.
From a Technical Analysis Perspective, Is BDRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Biodexa Pharmaceuticals DRC Trade On?
Biodexa Pharmaceuticals DRC is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Biodexa Pharmaceuticals DRC?
The stock symbol for Biodexa Pharmaceuticals DRC is "BDRX."
How Many Times Has Biodexa Pharmaceuticals DRC Stock Split?
Biodexa Pharmaceuticals DRC has split 8 times.
How Many Employees Does Biodexa Pharmaceuticals DRC Have?
Biodexa Pharmaceuticals DRC has 11 employees.
What Is the BDRX Premarket Price?
BDRX's last pre-market stock price is 4.500. The pre-market share volume is 89,260.000, and the stock has changed by 0.020, or 0.450%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.